biostudies-literatureUnknown8(7)Alonso-Solis AH2020 European Institute of Innovation and Technology<h4>Introduction</h4>Treatment-resistant schizophrenia (TRS) is a severe form of schizophrenia. In the European Union, approximately 40% of people with schizophrenia have TRS. Factors such as the persistence of positive symptoms or higher risk of comorbidities leave clinicians with a complex scenario when treating these patients. Intervention strategies based on mHealth have demonstrated their ability to support and promote self-management-based strategies. Mobile therapeutic attention for treatment-resistant schizophrenia <b>(</b>m-RESIST), an innovative mHealth solution based on novel technology and offering high modular and flexible functioning, has been developed specifically for patients with TRS and their caregivers. As intervention in TRS is a challenge, it is necessary to perform aBMJ opene021346https://www.ebi.ac.uk/biostudies/studies/S-EPMC6082494biostudies-literatureMobile therapeutic attention for treatment-resistant schizophrenia (m-RESIST): a prospective multicentre feasibility study protocol in patients and their caregivers.PMC6082494Alcalde FPapas ICoenen TRubinstein KTauro VTriantafillou AKoponen HJOchoa SUnoka ZVita IEscobar MIsohanni MAlmazan CSimonetti VMarco-Garcia SRubio-Abadal ED'amico EJewel CMentzas GKokkinakis PJamsa THuerta-Ramos EUsall JVella VABitter IKaye RBugheroni MGrasa EMStevens MCaro-Mendivelso JRoldan AJuola TKeymer-Gausset AHospedales MReixach Em-Resist groupFarkas KGimenez ECaspi AVan der Graff SMoilanen JSeppala JAlonso-Solis ABaccinelli WFazekas KSeppala AJaaskelainen EConstant XSebu GVermeir DBonizzi CCorripio IBerdun JParaskevopoulos FMiettunen JfalseMobile therapeutic attention for treatment-resistant schizophrenia (m-RESIST): a prospective multicentre feasibility study protocol in patients and their caregivers.<h4>Introduction</h4>Treatment-resistant schizophrenia (TRS) is a severe form of schizophrenia. In the European Union, approximately 40% of people with schizophrenia have TRS. Factors such as the persistence of positive symptoms or higher risk of comorbidities leave clinicians with a complex scenario when treating these patients. Intervention strategies based on mHealth have demonstrated their ability to support and promote self-management-based strategies. Mobile therapeutic attention for treatment-resistant schizophrenia <b>(</b>m-RESIST), an innovative mHealth solution based on novel technology and offering high modular and flexible functioning, has been developed specifically for patients with TRS and their caregivers. As intervention in TRS is a challenge, it is necessary to perform a2018-01-01T00:00:00Z2018 Jul2026-04-16T17:17:19.707Z2019-03-26T23:50:57ZS-EPMC60824943001278810.1136/bmjopen-2017-021346